1 published article · Updated continuously
7 trials tracked for Hypercholesterolaemia: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 139 citations.
Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Alirocumab has demonstrated significant reductions in calculated LDL-C levels across multiple trials. In a Phase 3 study, Alirocumab showed a reduction of 48.2% to 51.8% in LDL-C at week 24 (p<0.0001) 2. Another Phase 3 trial confirmed a reduction of 45.7% in LDL-C at week 24 (p<0.0001) 5. Additionally, Alirocumab SAR236553 (REGN727) showed significant reductions in LDL-C at week 24 (p<0.0001) 3 and week 8 (p<0.0001) 6.
Alirocumab SAR236553 (REGN727) also demonstrated a significant reduction in Apolipoprotein B (Apo B) at week 24 (p<0.0001) 3. In a Phase 2 study, Alirocumab SAR236553 (REGN727) showed a reduction in LDL-C at week 8 (p<0.0001), with a high percentage of participants achieving LDL-C levels below 130 mg/dL (3.37 mmol/L) 6.
Switching to a ritonavir-boosted PI was associated with a significant reduction in total cholesterol at 12 weeks (p=0.003) 1. Regarding administration safety, a study on Alirocumab SAR236553 reported a 0.5% rate of product technical complaints (PTCs) for unsupervised injections and 0% for supervised injections 4.
AI synthesis of 7 cited trials, updated Sep 17, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
